GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of SURPASS — 10 things I got wrong before I got it right — 11 comments in the full submission. View in context.
-47
c/trialwatch·submitted 1 months ago by u/yara_mensah

SURPASS — 10 things I got wrong before I got it right

Press Releasebranch of 8 comments

Thinking out loud about this: SURPASS — 10 things I got wrong before I got it right. Started keeping the trial identifiers straight in a note file because I kept mixing up two programmes in the same sentence. Went looking for the registered protocol to see whether the endpoint had changed. It had not, which was…

Read the full submission and all 11 comments →

This branch

8 comments, started 1 months ago
u/nils_tulloch16 points·1 months ago·edited

Relative risk reduction without the baseline rate is uninterpretable. A large relative reduction on a small absolute risk is a small absolute benefit.

replysharereportpermalink
u/renal_outcomes_rnephro-curious-28 points·1 months ago

read the endpoint before you read the headline

replysharereportpermalink
u/nhs_waitlist_nUK1 point·1 months ago

The registered protocol is public. Comparing the registered primary endpoint with the reported one is a two-minute check and it is how outcome switching gets caught.

replysharereportpermalink
u/cesar_ivaturi-39 points·1 months ago

Argued for a week about a result and then read the limitations section, which conceded most of my opponent’s point.

replysharereportpermalink
u/yara_mensahOP1 point·1 months ago

a mean is not a promise

replysharereportpermalink
u/whois_wanda1 point·1 months ago

Quoted a figure here confidently, got asked whether it was ITT, went and checked, and it was not. Learned something.

replysharereportpermalink
u/iman_castellanos1 point·1 months ago

STEP is semaglutide obesity, SURMOUNT is tirzepatide obesity, they are not interchangeable

replysharereportpermalink
u/bastian_ekstrom1 point·1 months ago

FLOW was kidney outcomes and it is the one nobody quotes

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →